Vivian Pan

Ms. Vivian Pan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GJGail P. Jarvik
Gail P. Jarvik
LALaura M. Amendola
Laura M. Amendola
JBJonathan S. Berg
Jonathan S. Berg
KBKyle Brothers
Kyle Brothers
ECEllen Clayton
Ellen Clayton
KSKathie Sun
Kathie Sun

24 June 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
LRL J Rasmussen-Torvik
L J Rasmussen-Torvik
SSS C Stallings
S C Stallings
AGA S Gordon
A S Gordon
BAB Almoguera
B Almoguera
MBM A Basford
M A Basford
JDJ C Denny
J C Denny
We describe here the design and initial implementation of the eMERGE‐PGx project. eMERGE‐PGx, a partnership of the Electronic Medical Records and Genomics Network and the Pharmacogenomics Research Ne...

11 August 2015 in Journal of Medical Genetics
Verified
Journal Article
Closed access
CDCori DeSanto
Cori DeSanto
KDKristin D'ACo
Kristin D'ACo
GAGabriel C Araujo
Gabriel C Araujo
NSNora Shannon
Nora Shannon
DSDDD Study
DDD Study
MSMarwan Shinawi
Marwan Shinawi
Background: Rare de novo mutations have been implicated as a significant cause of idiopathic intellectual disability. Large deletions encompassing 10p11.23 have been implicated in developmental delay, behavioural abnormalities and dysmorphic features, but the genotype–phenotype correlation was not delineated. Mutations in WAC have been recently reported in large screening cohorts of patients with intellectual disability or autism, but no full phenotypic characterisation was described. Methods: Clinical and molecular characterisation of six patients with loss-of-function WAC mutations identified by whole exome sequencing was performed. Clinical data were obtained by retrospective chart review, parental interviews, direct patient interaction and formal neuropsychological evaluation. Results: Five heterozygous de novo WAC mutations were identified in six patients. Three of the mutations were nonsense, and two were frameshift; all are predicted to cause loss of function either through nonsense-mediated mRNA decay or protein truncation. Clinical findings included developmental delay (6/6), hypotonia (6/6), behavioural problems (5/6), eye abnormalities (5/6), constipation (5/6), feeding difficulties (4/6), seizures (2/6) and sleep problems (2/6). All patients exhibited common dysmorphic features, including broad/prominent forehead, synophrys and/or bushy eyebrows, depressed nasal bridge and bulbous nasal tip. Posteriorly rotated ears, hirsutism, deep-set eyes, thin upper lip, inverted nipples, hearing loss and branchial cleft anomalies were also noted. Conclusions: Our case series show that loss-of-function mutations in WAC cause a recognisable genetic syndrome characterised by a neurocognitive phenotype and facial dysmorphism. Our data highly suggest that WAC haploinsufficiency is responsible for most of the phenotypic features associated with deletions encompassing 10p11.23.

1 August 2016 in Genetics in Medicine
Verified
Journal Article
Closed access
VPVivian Pan
Vivian Pan
BYBeverly M. Yashar
Beverly M. Yashar
RPRachel Pothast
Rachel Pothast
CWCatherine Wicklund
Catherine Wicklund

28 May 2025 in Journal of Genetic Counseling
Verified
Journal Article
Open access
BRBrian Reys
Brian Reys
AVAlyssa Valentine
Alyssa Valentine
VPVivian Pan
Vivian Pan
DGDelaney Gaston
Delaney Gaston
MHMardarius Harper
Mardarius Harper
RNRegina Nuccio
Regina Nuccio
Payer enrollment for genetic counselors (GCs) is fundamental to long‐term field sustainability and patient care access. Until federal recognition is obtained, enhancing Medicaid policies may help address existing GC coverage disparities. Understanding the current landscape is critical to mapping an effective strategy for future advocacy efforts. This study assessed GC provider enrollment and relevant CPT® codes across Medicaid programs in the United States via a review of open‐access Medicaid websites for 50 US states, Washington, DC, and 5 US territories in 2024. Medicaid fee status for CPT® code 96040 (GC only, 30 min) and S0265 (GC with physician supervision, 15 min code), fee schedule dates, availability of GC as a provider enrollment type, and state licensure status were abstracted. Of Medicaid provider enrollment websites for US states and DC, 21.6% (11/51) included genetic counselors; 49% (25/51) listed CPT® code 96040 and 13.7% (7/51) listed S0265 in the fee schedule with a non‐zero rate; none of the US territories listed either. Of the 34 regions with GC licensure, 32.4% (11/34) included GCs as an enrollment type in their state Medicaid provider website, while none of the 22 unlicensed regions did. This assessment highlights a gap between state licensure efforts and enrollment of GCs by state payers. Advocacy and public health policy directly targeting state Medicaid programs provide another avenue to increase coverage for GC services. A key downstream benefit of GC recognition through these efforts includes expanding access to genetic counseling services for underserved communities.

1 June 2025
Verified
Journal Article
Open access
VPVivian Pan
Vivian Pan
NBNatasha Robin Berman
Natasha Robin Berman
SBSasha Bauer
Sasha Bauer
MBMegan Bell
Megan Bell
KBKennedy Borle
Kennedy Borle
JAJehannine J Austin
Jehannine J Austin
The integration of genetic counselors (GCs) into primary care represents an opportunity for a transformative shift in healthcare delivery, bridging the gap between the historical medical genetics delivery model and the increasing need for genetic services. This paradigm aligns the holistic ethos of primary care with the specialized expertise of genetic counseling and frontline access to preventive care, addressing critical barriers in genetic services. Current genetic service delivery models, concentrated in tertiary care settings, face limitations, including access disparities, fragmented care, and inefficiencies that disproportionately affect underserved populations. Embedding GCs within primary care leverages GCs' unique skills to enhance personalized healthcare delivery, improve risk assessment, and facilitate the implementation of precision medicine. GCs in primary care can streamline referrals, manage routine genetic concerns, and provide genetic continuity of care across the patient's lifespan. This integration ensures that genetic insights are contextualized within patients' day-to-day healthcare, fostering equitable and efficient access to genomic medicine. We explore the potential impact of primary care genetic counselors (PCGCs) on healthcare systems, emphasizing the alignment of their scope of practice with primary care principles such as accessibility, comprehensiveness, and continuity. By addressing evolving patient needs and collaborating with primary care teams, PCGCs can increase patient access, reduce system inefficiencies, alleviate pressures on specialty genetics services, and improve health equity. This paper advocates for a collaborative model where GCs are embedded within primary care, enabling proactive, prevention-focused interventions and enhancing patient outcomes. By integrating genetics into primary care settings, we reimagine genetic healthcare delivery to maximize the benefits of genomic medicine for all individuals. This paradigm shift underscores the urgency of addressing systemic barriers and advancing the role of GCs in healthcare to improve patient and clinician experiences, better population health, and achieve greater health equity.